SERO-Ab testing
Research type
Research Study
Full title
Covid19 Serological antibody testing in samples surplus to clinical diagnosis
IRAS ID
283088
Contact name
William Irving
Contact email
Sponsor organisation
Nottingham University Hospitals NHS Trust
Duration of Study in the UK
1 years, 0 months, 7 days
Research summary
Serological tests for immunity to the coronavirus SARS-CoV-2 are in their infancy, and not widely available. We will establish and validate Enzyme-linked Immunosorbent assays (ELISA) for screening for IgG, A and M responses to multiple proteins of SARS-CoV-2 to support understanding of the scope of protective immunity generated in the population. We will link the antibody response to clinical outcome of the patients to give us a better understanding of the role of antibodies in providing protection
Excess serum samples remaining after routine diagnostic procedures have been stored by local NHS Clinical Chemistry Laboratories. These samples are from hospitalised individuals with proven SARS-CoV-2 infection.
This multidisciplinary study will be conducted in the University of Nottingham Virology and Immunology laboratories.
The study will last for 1 year and participants will have blood serum examined for the antibody responses to Covid19 proteins. In addition, sera will be used in neutralisation assays to determine the effectiveness of
patient antibodies to halt viral infection (using non-infectious pseudovirus particles) and cytokine measurements.REC name
N/A
REC reference
N/A